A human leucyl-tRNA synthetase as an anticancer target

Guangwei Gao,* Ying Yao,* Kun Li, Dhahiri Saidi Mashausi, Dongsheng Li, Hema Negi, Suchitra Kamle, Hao Chen, Zhenghua Wu, Huchen Zhou, Dawei Li School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People’s Republic of China *These authors contributed equally to this work...

Full description

Bibliographic Details
Main Authors: Gao G, Yao Y, Li K, Mashausi DS, Li D, Negi H, Kamle S, Chen H, Wu Z, Zhou H
Format: Article
Language:English
Published: Dove Medical Press 2015-10-01
Series:OncoTargets and Therapy
Online Access:https://www.dovepress.com/a-human-leucyl-trna-synthetase-as-an-anticancer-target-peer-reviewed-article-OTT
id doaj-8468fb9a468a4fbc9da0d592a11620d8
record_format Article
spelling doaj-8468fb9a468a4fbc9da0d592a11620d82020-11-25T02:48:12ZengDove Medical PressOncoTargets and Therapy1178-69302015-10-012015default2933294224173A human leucyl-tRNA synthetase as an anticancer targetGao GYao YLi KMashausi DSLi DNegi HKamle SChen HWu ZZhou HLi DGuangwei Gao,* Ying Yao,* Kun Li, Dhahiri Saidi Mashausi, Dongsheng Li, Hema Negi, Suchitra Kamle, Hao Chen, Zhenghua Wu, Huchen Zhou, Dawei Li School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: Several aminoacyl-tRNA synthetases have been reported to be overexpressed for charging essential aminoacyl-tRNAs in many cancer types. In this study, we aimed to explore the potential role of leucyl-tRNA synthetase (LARS) as an anticancer target. MTT assay was performed to screen inhibitors to human LARS (hsLARS) from compounds AN2690 and its derivatives, compounds 1–6, in U2OS and SKOV3 cells. The compound with the strongest inhibitory ability was further investigated for its inhibitory effect in cancer cell lines and in an animal tumor model. Additionally, a LARS-rescue experiment was performed to explore the potential target in U2OS using Western blot and flow cytometry. Luciferase reporter assay was designed to analyze the effect of of hsLARS inhibitor on p21 activation. We identified an hsLARS inhibitor (compound 2) that suppressed the proliferation of U2OS and SKOV3 cells in vitro. A LARS-rescue experiment demonstrated that the proliferation inhibition was induced by targeting intracellular LARS. In addition, the hsLARS inhibition was shown to activate the p21 early transcription and promote cell apoptosis, as well as reduce implanted EMT6 tumor progression in mice. Our results suggest that LARS might serve as a potential anticancer target through the p21 signaling pathway and that the nutritional signaling pathway may provide a valuable anticancer strategy for further investigation. Keywords: leucyl-tRNA synthetase, apoptosis, mouse model, anticancer targethttps://www.dovepress.com/a-human-leucyl-trna-synthetase-as-an-anticancer-target-peer-reviewed-article-OTT
collection DOAJ
language English
format Article
sources DOAJ
author Gao G
Yao Y
Li K
Mashausi DS
Li D
Negi H
Kamle S
Chen H
Wu Z
Zhou H
Li D
spellingShingle Gao G
Yao Y
Li K
Mashausi DS
Li D
Negi H
Kamle S
Chen H
Wu Z
Zhou H
Li D
A human leucyl-tRNA synthetase as an anticancer target
OncoTargets and Therapy
author_facet Gao G
Yao Y
Li K
Mashausi DS
Li D
Negi H
Kamle S
Chen H
Wu Z
Zhou H
Li D
author_sort Gao G
title A human leucyl-tRNA synthetase as an anticancer target
title_short A human leucyl-tRNA synthetase as an anticancer target
title_full A human leucyl-tRNA synthetase as an anticancer target
title_fullStr A human leucyl-tRNA synthetase as an anticancer target
title_full_unstemmed A human leucyl-tRNA synthetase as an anticancer target
title_sort human leucyl-trna synthetase as an anticancer target
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2015-10-01
description Guangwei Gao,* Ying Yao,* Kun Li, Dhahiri Saidi Mashausi, Dongsheng Li, Hema Negi, Suchitra Kamle, Hao Chen, Zhenghua Wu, Huchen Zhou, Dawei Li School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: Several aminoacyl-tRNA synthetases have been reported to be overexpressed for charging essential aminoacyl-tRNAs in many cancer types. In this study, we aimed to explore the potential role of leucyl-tRNA synthetase (LARS) as an anticancer target. MTT assay was performed to screen inhibitors to human LARS (hsLARS) from compounds AN2690 and its derivatives, compounds 1–6, in U2OS and SKOV3 cells. The compound with the strongest inhibitory ability was further investigated for its inhibitory effect in cancer cell lines and in an animal tumor model. Additionally, a LARS-rescue experiment was performed to explore the potential target in U2OS using Western blot and flow cytometry. Luciferase reporter assay was designed to analyze the effect of of hsLARS inhibitor on p21 activation. We identified an hsLARS inhibitor (compound 2) that suppressed the proliferation of U2OS and SKOV3 cells in vitro. A LARS-rescue experiment demonstrated that the proliferation inhibition was induced by targeting intracellular LARS. In addition, the hsLARS inhibition was shown to activate the p21 early transcription and promote cell apoptosis, as well as reduce implanted EMT6 tumor progression in mice. Our results suggest that LARS might serve as a potential anticancer target through the p21 signaling pathway and that the nutritional signaling pathway may provide a valuable anticancer strategy for further investigation. Keywords: leucyl-tRNA synthetase, apoptosis, mouse model, anticancer target
url https://www.dovepress.com/a-human-leucyl-trna-synthetase-as-an-anticancer-target-peer-reviewed-article-OTT
work_keys_str_mv AT gaog ahumanleucyltrnasynthetaseasananticancertarget
AT yaoy ahumanleucyltrnasynthetaseasananticancertarget
AT lik ahumanleucyltrnasynthetaseasananticancertarget
AT mashausids ahumanleucyltrnasynthetaseasananticancertarget
AT lid ahumanleucyltrnasynthetaseasananticancertarget
AT negih ahumanleucyltrnasynthetaseasananticancertarget
AT kamles ahumanleucyltrnasynthetaseasananticancertarget
AT chenh ahumanleucyltrnasynthetaseasananticancertarget
AT wuz ahumanleucyltrnasynthetaseasananticancertarget
AT zhouh ahumanleucyltrnasynthetaseasananticancertarget
AT lid ahumanleucyltrnasynthetaseasananticancertarget
AT gaog humanleucyltrnasynthetaseasananticancertarget
AT yaoy humanleucyltrnasynthetaseasananticancertarget
AT lik humanleucyltrnasynthetaseasananticancertarget
AT mashausids humanleucyltrnasynthetaseasananticancertarget
AT lid humanleucyltrnasynthetaseasananticancertarget
AT negih humanleucyltrnasynthetaseasananticancertarget
AT kamles humanleucyltrnasynthetaseasananticancertarget
AT chenh humanleucyltrnasynthetaseasananticancertarget
AT wuz humanleucyltrnasynthetaseasananticancertarget
AT zhouh humanleucyltrnasynthetaseasananticancertarget
AT lid humanleucyltrnasynthetaseasananticancertarget
_version_ 1724749177879003136